Dry CNP Conjugate Formulations for Premature Release Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical formulations of CNP conjugates face challenges in achieving stable storage due to premature CNP release and degradation, leading to potential overdosage and reduced therapeutic efficacy, especially in pediatric populations.
Innovation Solution
A dry pharmaceutical formulation comprising a CNP conjugate covalently and reversibly linked to a polymeric moiety, along with a buffering agent and a bulking agent, which stabilizes the CNP conjugate during long-term storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CNP conjugates are stored in aqueous formulations, then the CNP moiety remains soluble and bioactive, but the reversible linkage degrades during storage causing premature CNP release and potential overdosage
Solution Approach 1:
The patent transforms the formulation from aqueous to dry/powder form, fundamentally changing the physical state parameter. This prevents hydrolysis of the reversible linkage while maintaining CNP bioactivity through lyophilization, resolving the contradiction between stability and premature release
Solution Approach 2:
The patent introduces a freezing/drying intermediary process that temporarily alters the formulation state. By freezing and then subliming the aqueous formulation, the reversible linkage is protected from degradation while the CNP moiety is preserved in a stable dry state for later reconstitution
2Reliability
If CNP is administered continuously via intravenous infusion, then therapeutic efficacy is maintained, but the short half-life requires complex continuous delivery infrastructure
Solution Approach 1:
The patent performs preliminary action by conjugating CNP to a polymer beforehand, creating a reservoir that slowly releases the active moiety. This pre-prepared conjugate eliminates the need for continuous infusion equipment while maintaining therapeutic levels through controlled release
Solution Approach 2:
The patent achieves continuity of useful action through the polymer-CNP conjugate that provides sustained release of the active moiety over time. The slow degradation of the reversible linkage ensures continuous therapeutic delivery without requiring ongoing external intervention or infusion equipment
3Stability of the object's composition
If the reversible linkage between polymer and CNP is degraded during storage, then the CNP concentration increases, but this leads to overdosage risk and hypotension
Solution Approach 1:
The patent changes the storage parameter from aqueous to dry state, which stabilizes the reversible linkage and prevents degradation. This parameter change eliminates the source of premature CNP release and associated overdosage risks
Solution Approach 2:
The patent applies preliminary anti-action by using the dry formulation approach to prevent linkage degradation before it can occur during storage. This preemptive measure blocks the pathway to CNP release and potential harmful effects
Data Source
AI summary
A dry pharmaceutical formulation, wherein the pharmaceutical formulation comprises a CNP conjugate, a buffering agent and a bulking agent and wherein the CNP conjugate comprises a CNP moiety that is covalently and reversibly conjugated to a polymeric moiety.